Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glimepiride - Sanofi

Next Previous
Drug Profile

Glimepiride - Sanofi

Alternative Names: Amarel; Amaril; Amaryl; HOE-490; Roname

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Lacer; Sanofi; Shandong Zibo - Xinhua - Chemferm (JV)
  • Class Antihyperglycaemics; Small molecules; Sulfonylureas
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 27 Jul 2022 Lacer has been acquired by Italfarmaco
  • 31 Jan 2014 Sanofi completes the phase III RECOMMEND trial in Type-2 diabetes mellitus (combination therapy) in Algeria, Colombia, Egypt, Guatemala, India, Iran, Lebanon, Mexico, Russia, Saudi Arabia, South Africa, Tunisia, Turkey, Ukraine and the United Arab Emirates (NCT01459809)
  • 16 Feb 2012 Phase-III clinical trials in Type-2 diabetes mellitus (combination therapy) in Algeria, Colombia, Egypt, India, Iran, Lebanon, Mexico, Russia, Saudi Arabia, South Africa, Tunisia, Turkey, Ukraine and United Arab Emirates (Oral) after February 2012

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top